Supplementary Material for: Early Treatment with Human Albumin Solution in Continuous Renal Replacement Patients

<b><i>Aims:</i></b> To study the impact of early human albumin solution (HAS) in continuous renal replacement therapy (RRT) patients. <b><i>Methods:</i></b> Analysis of Randomized Evaluation of Normal versus Augmented Level (RENAL) RRT trial data. <b><i>Results:</i></b> Of 1,464 patients, 500 (34%) received early albumin. These patients had higher illness severity scores, greater use of mechanical ventilation, and 90-day mortality (51 vs. 41%; <i>p</i> &lt; 0.001). However, early albumin carried similar RRT dependence risk among survivors at day 90 (4.9 vs. 5.8%; <i>p</i> = 0.62). On Cox proportional hazards regression, with standardized inverse probability of treatment weighting, early albumin was not associated with increased mortality (hazard ratio [HR]: 1.23, 95% CI: 0.97–1.55; <i>p</i> = 0.09) or recovery to RRT independence (HR: 0.92, 95% CI: 0.78–1.10; <i>p</i> = 0.38). <b><i>Conclusions:</i></b> Early albumin was administered to one-third of RENAL trial patients and in those with greater illness severity. Early albumin was not independently associated with mortality risk or rate of recovery to RRT independence.